TY - JOUR T1 - Circulating lipids associate with future weight gain in individuals with an at-risk mental state and in first-episode psychosis JF - medRxiv DO - 10.1101/2020.01.30.20019711 SP - 2020.01.30.20019711 AU - Santosh Lamichhane AU - Alex M. Dickens AU - Partho Sen AU - Heikki Laurikainen AU - Jaana Suvisaari AU - Tuulia Hyötyläinen AU - Oliver Howes AU - Jarmo Hietala AU - Matej Orešič Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/03/2020.01.30.20019711.abstract N2 - Patients with schizophrenia have a lower than average life span, largely due to the increased prevalence of cardiometabolic co-morbidities. Identification of individuals with psychotic disorders with a high risk of rapid weight gain, and the associated development of metabolic complications, is an unmet need as regards public health. Here, we applied mass spectrometry-based lipidomics in a prospective study comprising 48 controls (CTR), 44 first-episode psychosis (FEP) patients and 22 individuals at clinical-high-risk (CHR) for psychosis, from two study centers (Turku/Finland and London/UK). Baseline serum samples were analyzed by lipidomics, while body mass index (BMI) was assessed at baseline and after 12 months. We found that baseline triacylglycerols with low double bond counts and carbon numbers were positively associated with the change in BMI at follow-up. In addition, a molecular signature comprised of two triacylglycerols (TG(48:0) and TG(45:0)), was predictive of weight gain in individuals with a psychotic disorder, with an area under the receiver operating characteristic curve (AUROC) of 0.74 (95% CI: 0.60–0.85). When independently tested in the CHR group, this molecular signature predicted said weight change with AUROC = 0.73 (95% CI: 0.61–0.83). We conclude that molecular lipids may serve as a predictor of weight gain in psychotic disorders in at-risk individuals, and may thus provide a useful marker for identifying individuals who are most prone to developing cardiometabolic co-morbidities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the European Union’s Seventh Framework Programme for the project “Neuroimaging platform for characterization of metabolic co-morbidities in psychotic disorders” (METSY; agreement no. 602478).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe lipidomics dataset and the relevant clinical metadata generated in this study were submitted to MetaboLights database, under accession number MTBLS1467. ER -